Aerpio Pharmaceuticals is a biopharmaceutical company focused on advancing first-in-class treatments for ocular disease. Aerpioâs lead product candidate, AKB-9778, a small molecule activator of the Tie-2 pathway, is being developed for the treatment of non-proliferative diabetic retinopathy. In contrast to marketed treatments for non-proliferative diabetic retinopathy that are administered by a physician via intraocular injection, AKB-9778 is delivered systemically by self-administered subcutaneous injection. We believe this delivery method provides an opportunity to treat patients at an earlier stage of disease, potentially reducing the likelihood of these patients developing vision-threatening complications. Source
No articles found.
Love Goodly is on a mission to help women love their bodiesâŚ.and feel good about...
Love Goodly is on a mission to help women love ...
Kamada Ltd. is focused on plasma-derived protein therapeutics for orphan indicatio...
Kamada Ltd. is focused on plasma-derived protei...
Carie Health is a mobile healthcare solution that allows members to connect with a...
Carie Health is a mobile healthcare solution th...
Alterola Biotech Inc. provides medicinal delivery systems, offering nutraceutrical...
Alterola Biotech Inc. provides medicinal delive...
Apollo Endosurgery, Inc. is a medical device company focused on less invasive ther...
Apollo Endosurgery, Inc. is a medical device co...
We are a gene therapy company dedicated to developing and commercializing novel tr...
We are a gene therapy company dedicated to deve...
Acacia Diversified Holdings, Inc., is an emerging hemp company, through its wholly...
Acacia Diversified Holdings, Inc., is an emergi...
Join the National Investor Network and get the latest information with your interests in mind.